HUP0003106A2 - Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma - Google Patents

Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma

Info

Publication number
HUP0003106A2
HUP0003106A2 HU0003106A HUP0003106A HUP0003106A2 HU P0003106 A2 HUP0003106 A2 HU P0003106A2 HU 0003106 A HU0003106 A HU 0003106A HU P0003106 A HUP0003106 A HU P0003106A HU P0003106 A2 HUP0003106 A2 HU P0003106A2
Authority
HU
Hungary
Prior art keywords
glaucoma
treatment
effects
prostaglandin derivatives
derivatives devoid
Prior art date
Application number
HU0003106A
Other languages
Hungarian (hu)
Inventor
Staffan Lake
Bahram Resul
Johan Stjernschantz
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20407743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0003106(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Publication of HUP0003106A2 publication Critical patent/HUP0003106A2/en
Publication of HUP0003106A3 publication Critical patent/HUP0003106A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Abstract

Atalálmány tárgyát új eljárás és készítmény képezi glaukóma és magasszemnyomás kezelésére. Az eljárás EP1 prosztanoidreceptor-agonistahatású vegyületek felhasználásán alapul, amelyek hatásosan csökkentikaz intraokuláris nyomást, de nincs vagy csökkentett azíriszpigmentációra kifejtett hatásuk. Az EP1 szelektív agonistaprosztaglandinanalógot a szemen topikusan alkalmazzák. ÓThe subject of the invention is a new method and preparation for the treatment of glaucoma and high eye pressure. The procedure is based on the use of EP1 prostanoid receptor agonist compounds, which effectively reduce intraocular pressure, but have no or reduced effect on azirispigmentation. The EP1 selective agonist prostaglandin analog is applied topically to the eye. HE

HU0003106A 1997-07-11 1998-07-10 Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma HUP0003106A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9702706A SE9702706D0 (en) 1997-07-11 1997-07-11 Prostaglandin derivatives devoid of side effects for the treatment of glaucoma

Publications (2)

Publication Number Publication Date
HUP0003106A2 true HUP0003106A2 (en) 2001-01-29
HUP0003106A3 HUP0003106A3 (en) 2002-12-28

Family

ID=20407743

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0003106A HUP0003106A3 (en) 1997-07-11 1998-07-10 Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma

Country Status (19)

Country Link
EP (1) EP1014991A1 (en)
JP (1) JP2002509543A (en)
KR (1) KR20010021682A (en)
CN (1) CN1169528C (en)
AU (1) AU739828B2 (en)
BR (1) BR9815501A (en)
CA (1) CA2294779A1 (en)
HK (1) HK1029942A1 (en)
HU (1) HUP0003106A3 (en)
IL (1) IL133871A (en)
IS (1) IS5333A (en)
NO (1) NO20000062D0 (en)
NZ (1) NZ501834A (en)
PL (1) PL337940A1 (en)
RU (1) RU2207858C2 (en)
SE (1) SE9702706D0 (en)
SK (1) SK183499A3 (en)
TR (1) TR200000008T2 (en)
WO (1) WO1999002165A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9803761D0 (en) * 1998-11-04 1998-11-04 Synphora Ab Method to avoid increased iridial pigmentation during prostaglandin treatment
NZ513825A (en) 1999-03-05 2001-09-28 Procter & Gamble C 16 unsaturated FP-selective prostaglandins analogs
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US6531504B2 (en) * 2001-05-17 2003-03-11 Allergan, Inc. Prostanoic acid derivatives as agents for lowering intraocular pressure
GB0112699D0 (en) 2001-05-24 2001-07-18 Resolution Chemicals Ltd Process for the preparation of prostglandins and analogues thereof
US6713268B2 (en) * 2001-06-26 2004-03-30 Allergan, Inc. Methods of identifying ocular hypotensive compounds having reduced hyperpigmentation
WO2004031142A2 (en) * 2002-09-16 2004-04-15 Texas Tech University System Inhibition of metallo-beta-lactamase
GB0501192D0 (en) 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
PL212658B1 (en) * 2005-04-18 2012-11-30 Inst Farmaceutyczny Method for obtaining the derivatives of 13,14-dihydro-PGF₂α
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US20110038884A1 (en) 2008-04-28 2011-02-17 National University Co., Hamamatsu Univer. School Of Medicine Immunopotentiating agent comprising ep1 agonist
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
EP3828172A1 (en) 2009-05-01 2021-06-02 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
CA2777290C (en) 2009-10-16 2016-06-28 Cayman Chemical Company, Incorporated Process for the preparation of f-series prostaglandins
EA027416B1 (en) 2012-03-28 2017-07-31 Мерк Патент Гмбх Bicyclic pyrazinone derivatives
JP2012246301A (en) * 2012-08-10 2012-12-13 Cayman Chemical Co Inc Method for preparing prostaglandins f
EP3811943B1 (en) 2013-03-15 2023-02-22 Aerie Pharmaceuticals, Inc. Compound for use in the treatment of ocular disorders
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
US11389441B2 (en) 2016-08-31 2022-07-19 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
MX2019011784A (en) 2017-03-31 2019-11-18 Aerie Pharmaceuticals Inc Aryl cyclopropyl-amino-isoquinolinyl amide compounds.
EP3849555A4 (en) 2018-09-14 2022-05-04 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4132738A (en) * 1978-02-23 1979-01-02 Miles Laboratories, Inc. Preparation of 15-deoxy-16-hydroxyprostaglandins
EP0664707B1 (en) * 1992-10-13 1997-06-04 Alcon Laboratories, Inc. Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma

Also Published As

Publication number Publication date
JP2002509543A (en) 2002-03-26
KR20010021682A (en) 2001-03-15
SK183499A3 (en) 2000-07-11
PL337940A1 (en) 2000-09-11
CA2294779A1 (en) 1999-01-21
CN1262623A (en) 2000-08-09
CN1169528C (en) 2004-10-06
RU2207858C2 (en) 2003-07-10
HK1029942A1 (en) 2001-04-20
IS5333A (en) 2000-01-07
NO20000062L (en) 2000-01-06
IL133871A0 (en) 2001-04-30
AU8368398A (en) 1999-02-08
WO1999002165A1 (en) 1999-01-21
EP1014991A1 (en) 2000-07-05
BR9815501A (en) 2001-07-17
TR200000008T2 (en) 2000-05-22
SE9702706D0 (en) 1997-07-11
NZ501834A (en) 2002-05-31
AU739828B2 (en) 2001-10-18
IL133871A (en) 2004-09-27
HUP0003106A3 (en) 2002-12-28
NO20000062D0 (en) 2000-01-06

Similar Documents

Publication Publication Date Title
HUP0003106A2 (en) Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma
HK1027748A1 (en) Use of 3-benzoyl-phenylacetic acids, esters, or amides for treatment of glcia glaucoma
TWI255714B (en) Method for treating meibomian gland disease
NO20012977D0 (en) N-ureidoalkylpiperidines as modulators of chemokine receptor activity
EP1225168B8 (en) Prostaglandin-F-2 alpha derivative for the treatment of glaucoma or ocular hypertension
AU3126600A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
HUP9802999A2 (en) Pharmaceutical composition containing n-propargyl-1-aminoindan
AU1709699A (en) 13-oxa prostaglandins for the treatment of glaucoma and ocular hypertension
AU5436198A (en) 11-halo prostaglandins for the treatment of glaucoma or ocular hypertension
DK1302207T3 (en) Process for preparing an antihypertensive agent containing a dipeptide as an effective ingredient
ATE78031T1 (en) PROSTAGLANDIN DERIVATIVES FOR THE TREATMENT OF GLAUCOMA OR OCULAR PRESSURE.
HUP9801243A2 (en) Sterile ophthalmological gel preparation applicable in drops and process for producing it
DK1395263T3 (en) 3, 7 or 3 and 7 thia or oxaprostanoic acid derivatives as agents for lowering intraocular pressure
AU5355498A (en) 15-fluoro prostaglandins as ocular hypotensives
AU2211700A (en) Prostaglandin e agonists for treatment of glaucoma
GB2380939B (en) Treatment or prevention of auto-immune diseases
BG102064A (en) Method for increasing the retinal blood circulation
HUP0103206A2 (en) A device and method for the treatment of erectile dysfunction and for its making
BR9812085A (en) "method for the synthesis of quinoline derivatives"
WO2002072105A3 (en) Improved prostanoid therapies for the treatment of glaucoma
AR030346A1 (en) METHOD OF TREATMENT OF NEURODEGENERATIVE DISORDERS OF THE RETINA AND HEAD OF OPTICAL NERVE
SE9401087D0 (en) New prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
CA2200481A1 (en) Method and means for prevention and treatment of secondary cataract
ATE289817T1 (en) MEDICINAL COMPOSITION FOR THE TREATMENT OF INCREASED EYE PRESSURE OR GLAUCOMA
AU2001270642A1 (en) Method for the treatment of glaucoma and ocular hypertension by administering nucleotides